



Aviragen Therapeutics, Inc.  
Investor Relations Department  
2500 Northwinds Parkway  
Suite 100  
Alpharetta, GA 30009  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

**NASDAQ: AVIR**

|               |                            |
|---------------|----------------------------|
| Last Trade:   | 0.60                       |
| Trade Time:   | 4:00 PM ET<br>Aug 18, 2017 |
| Change:       | 0.03  (+4.614%)            |
| Day Range     | 0.58 - 0.60                |
| 52-Week Range | 0.43 - 2.00                |
| Volume        | 39,638                     |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three Phase 2 clinical stage compounds: vapednavir, a capsid inhibitor for the prevention or treatment of rhinovirus (RV) upper respiratory infections; enzaplavovir (BTA585), a fusion protein inhibitor in development for the treatment of respiratory syncytial virus infections; and BTA074, an antiviral treatment for condyloma caused by human papill... [\(more\)](#)

## Stock Information



## Press Releases [\[ View all \]](#)

May 4, 2017

[Aviragen Therapeutics Reports Third Quarter Fiscal Year 2017 Financial Results](#)

Apr 4, 2017

[Aviragen Therapeutics Announces Review of Strategic Alternatives and Provides Corporate Update](#)

Feb 13, 2017

[Aviragen Therapeutics Announces Top-Line Results from Phase 2b SPIRITUS Trial of Vapednavir](#)

Feb 2, 2017

[Aviragen Therapeutics Reports Second Quarter Fiscal Year 2017 Financial Results](#)

Feb 1, 2017

[Aviragen Therapeutics Announces Top-Line Results from Phase 2a RSV Challenge Study of BTA585](#)

## Financials [\[ View all \]](#)

[Third Quarter Financial Results](#)

Sep 13, 2016

[Annual Report \(10-K\)](#)

Sep 27, 2016

[Proxy Statement \(DEF 14A\)](#)

May 8, 2017

[Quarterly Report \(10-Q\)](#)

Feb 6, 2017

[Quarterly Report \(10-Q\)](#)

Nov 8, 2016

[Quarterly Report \(10-Q\)](#)